Introduction/Background Although the role of lymph node dissection in the early stages of ovarian cancer is well established, with prognostic and therapeutic benefits, this has yet to be demonstrated in the advanced stages of ovarian cancer.

The aim of our study is to establish the impact of lymphadenectomy on survival rates in advanced ovarian cancer (AOC).

Methodology We retrospectively conducted a mono-centric, longitudinal, comparative study including all patients surgically managed for advanced stage ovarian cancer (FIGO IIB - IV) in the oncologic surgery department of the Salah Azaiez Institute, from January 2000 to December 2017.

We subdivided our patients into two groups according to whether or not they have had a lymph node dissection after a complete cytoreductive surgery.

Results After complete residual cytoreductive surgery, 70 patients had a lymphadenectomy (LN) and 12 did not (NoLN). Mean overall survival was 77.3 months±9.5 for LN patients and 34 months±5.9 for NoLN patients.

Overall survival was significantly better in the LN group. (p=0.007).

When the lymph nodes were macroscopically normal intraoperatively, and when the resection was carcinologically complete, there was no statistically significant difference in terms of overall survival depending on whether or not lymphadenectomy was performed.

The mean recurrence-free survival was 81.3±9.9 for LN patients and 24.5±4.5 for NoLN patients.

Recurrence-free survival was significantly better in patients who had LN.

Conclusion After a complete cytoreductive surgery for AOC with no residual disease, patients had a better survival rates after lymphadenectomy. However there was no benefit on survival from lymphadenectomy when lymph nodes were macroscopically normal.

Disclosures None.